Efficacy and safety of once-weekly insulins in type 2 diabetes: A systematic review and meta-analysis.

What the trial testedas reported · 2026

Not counted

−0.12percentage points−0.19 to −0.04

As reported

difference −0.12 %, 95% CI −0.19 to −0.04

Range includes no effect

+4%−21% to +28%

Smaller than almost all for glycemic control

As reported

IRR 1.04, 95% CI 0.79–1.28

the abstract, start to end

… or semaglutide (pooled mean difference: -0.12%, 95% CI: -0.19 to -0.04, …

… groups (pooled incidence rate ratio: 1.04, 95% CI: 0.79 to 1.28, …

← favours treatmentfavours comparator →

could be chance

Glycemic control

−0.12−0.19 to −0.04

Glycemic control

IRR 1.040.79–1.28

GLP-1 receptor agonistsInsulinGlycemic control

1 / 3